Insight Molecular Diagnostics Inc. (IMDX)

↓ Download CSV

CIK 0001642380 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

In fiscal 2025, Insight Molecular Diagnostics Inc. reported revenue of $4.05M, up 115.6% from the prior year. The company ran a net loss, with a net margin of -1238.5% and a gross margin of 56.7%. It held $25.76M in total assets against $57.22M in total liabilities.

Key ratios (FY2025)

56.7%
Gross margin
-1260.8%
Operating margin
-1238.5%
Net margin
+115.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$4.05M$1.88M$1.50M$958.0K$2.20M$1.22M
Cost of Revenue$1.75M$1.05M$1.00M$880.0K$697.0K$1.85M
Gross Profit$2.30M$740.0K$413.0K-$18.0K$1.42M-$639.0K
Operating Income-$51.12M-$61.04M-$25.14M-$18.00M-$53.73M-$29.71M-$22.24M-$15.20M-$18.85M-$11.14M
Net Income-$50.22M-$60.66M-$27.78M-$72.90M-$64.10M-$29.93M-$22.43M-$15.75M-$19.38M-$11.17M
EPS (Diluted)$-1.65$-4.66$-3.75$-13.25$-0.72
Total Assets$25.76M$35.08M$74.89M$100.09M$159.56M$55.42M$39.86M$9.52M$10.22M$14.45M
Total Liabilities$57.22M$47.35M$49.30M$60.50M$94.35M$21.94M$9.02M$6.09M$5.81M$4.58M
Shareholders' Equity-$31.46M-$12.27M$20.47M$34.29M$65.22M$33.48M$30.84M$3.42M$4.40M$9.86M
Cash & Equivalents$11.58M$8.64M$9.43M$19.99M$32.95M$7.14M$22.07M$8.03M$7.60M$10.17M
Operating Cash Flow-$22.18M-$20.69M-$23.32M-$45.57M-$35.94M-$25.98M-$19.71M-$11.65M-$13.38M-$7.52M
Capital Expenditures$3.19M$516.0K$281.0K$4.34M$2.25M$1.23M$918.0K$31.0K$91.0K$106.0K
Shares Outstanding28.68M17.45M8.26M5.93M92.23M69.12M57.03M40.66M31.45M28.74M